Turn Therapeutics Expects Q2 2026 Interim and Final Readouts for 214–220 Patient Phase II Eczema Trial
Turn Therapeutics is enrolling approximately 214–220 patients in its fully capitalized, phase III–sized GX-03 Phase II eczema trial with an independent interim assessment and final top-line readouts expected in Q2 2026. Its topical PermaFusion formulation delivered a 57% Investigator Global Assessment improvement in IL-36–induced models and recorded zero adverse reactions across 580 applications.
1. Adaptive Phase II Trial Design and Timeline
Turn Therapeutics is enrolling approximately 214–220 patients in its phase III–sized GX-03 randomized Phase II eczema trial. An independent interim assessment committee can recommend continuation, enrollment increases up to double the sample size, or trial termination for futility, with both interim and top-line results slated for Q2 2026.
2. Preclinical Efficacy and Safety Results
In an IL-36–induced in vivo model, GX-03 achieved a 57% reduction in Investigator Global Assessment over seven days. A 53-patient RAPT safety trial involving 580 topical applications recorded no adverse reactions, leveraging the formulation’s established wound care safety history.
3. PermaFusion Non-Systemic Topical Formulation
The PermaFusion mixing process suspends polar, water-soluble APIs in an oil-based carrier without emulsifiers, delivering high bioavailability at a low formula weight. Using petrolatum as the ointment base, the approach targets localized immunomodulation and avoids systemic exposure in moderate-to-severe inflammatory skin diseases.
4. Onychomycosis Program and Pipeline Expansion
The Phase III-ready onychomycosis candidate showed 70% efficacy with once-daily dosing and 85% with twice-daily in a 100-patient trial, and achieved 12–18% nail fungus reduction in two weeks. Turn is also exploring indications like hidradenitis suppurativa and chronic pruritus while maintaining a low burn rate, over seven patent families and 17 issued patents.